Results 241 to 250 of about 1,459,292 (318)

A Composite Ovine Forestomach Matrix and Hyaluronic Acid CAMP for the Treatment of Full Thickness Wounds of the Foot in People With Diabetes: A Randomized Controlled Trial

International Wound Journal, Volume 23, Issue 10, October 2026.
ABSTRACT Diabetic foot ulcers (DFUs) are a devastating complication of diabetes that markedly affects quality of life and generates significant socioeconomic and healthcare burdens. When DFUs fail to respond to standard of care (SOC), advanced therapies including Cellular, Acellular and Matrix‐like Products (CAMPs) are often employed. A novel composite
David G. Armstrong, Dennis P. Orgill, Robert D. Galiano, John C. Lantis, Paul Glat, Alexander M. Reyzelman, Robert J. Snyder, Adam L. Isaac, Marissa J. Carter, Charles M. Zelen   +9 more
wiley   +1 more source

SARS-CoV-2 Drug-Resistant Mutations in Non-Structural Proteins. [PDF]

Viruses
Shaw M, Fehr AR.
europepmc   +1 more source

Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response

Journal of Viral Hepatitis, Volume 33, Issue 10, October 2026.
ABSTRACT Standard durations of direct acting antivirals (DAAs; 8–12 weeks) can be a barrier to HCV treatment initiation and completion among marginalized populations. This study developed and internally validated a machine learning model to predict short‐duration (4–6 weeks) DAA response using baseline clinical factors with potential to improve ...
Joanne M. Carson, Sebastiano Barbieri, Andrey Verich, Elise Tu, Andrew Lloyd, Gregory J. Dore, Gail V. Matthews, Marianne Martinello   +7 more
wiley   +1 more source

Late-stage Diversification of HIV-1 Protease Inhibitor via SuFEx Click Chemistry. [PDF]

Synthesis (Stuttg)
Khanal B, Yamanushkin P, Gold B.
europepmc   +1 more source

Non-Canonical Binding of Nelfinavir in HIV-1 Protease Variants Reveals Structural Mechanisms of Antiretroviral Resistance. [PDF]

Viruses
Cadena-Cruz C, De Avila-Arias M, Guzmán F, Pérez M, Zuluaga MA, Navarro Quiroz E, Angulo A, Garcerant LEP, Rojas HR, Chica DAF, Cervantes G, Villarreal-Camacho JL.   +11 more
europepmc   +1 more source

Novel Bridged Tricyclic Carbamoylpyridone Compounds as HIV Integrase Inhibitors for Treating HIV Infection. [PDF]

ACS Med Chem Lett
Sabnis RW.
europepmc   +1 more source

Peptide‐Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives

ChemMedChem, Volume 21, Issue 18, 28 September 2026.
Peptide‐enabled nanoplatforms offer multifunctional strategies for the treatment and diagnosis of malaria and leishmaniasis. Liposomal, polymeric, and metallic nanocarriers, together with cell‐penetrating peptides and parasite‐derived mimotopes, can improve targeted drug delivery, stability, bioavailability, and intracellular localization.
Christian S. Carnero Canales, Ana Clara Lunardi Yagi, Túlio Custódio Reis, Jessica Ingrid Cazorla, Jade Rojas Villar, Marcia A. Graminha, Roxana Yesenia Pastrana Alta, Fernando Rogério Pavan   +7 more
wiley   +1 more source

Longitudinal Clinical and Molecular Characterization of a Single Pediatric Case of Vertically Acquired HIV-1 Subtype C with Baseline Resistance to Protease Inhibitors. [PDF]

Microorganisms
Zaher KA, El-Daly MM, Zaki EA, Alhazmi MM, Abdulhaq A, El-Kafrawy SA, Azhar EI.   +6 more
europepmc   +1 more source

HIV-1 transmitted drug resistance in Shanghai, 2018-2024: population mobility shapes cross-population TDR transmission dynamics. [PDF]

Emerg Microbes Infect
Dong Y, Lin Q, Wang X, Liu C, Yu X, Tang W, Feng W, Lv X, Han Y, Yue Q, Ning Z, Shen X, Chen X, Zhou Y, Chen M, Wu H, Lin Y.   +16 more
europepmc   +1 more source

The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches. [PDF]

New Microbes New Infect
Ahmadi Ghezeldasht S, Miri R, Shamsian SK, Mosavat A, Rezaee SA.   +4 more
europepmc   +1 more source